• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Insurers, States Strike Hepatitis C Deals

Article

Insurers and state Medicaid agencies have been eager to strike a deal with pharmaceutical companies to secure discounts on pricey hepatitis C drugs.

Both insurers and state Medicaid agencies are working to secure discounts on pricey hepatitis C drugs.

Insurers and states alike have been eager to strike a deal with the pharmaceutical companies, especially considering

the backlash Gilead's Sovaldi received last year after the company placed a $100,000 per person price tag on the drug. Harvoni is Gilead's follow-up to Sovaldi.

Missouri signed a deal with AbbVie this week to make Viekira Park the preferred drug covered by the state's Medicaid program, noted the Wall Street Journal

. The drug will replace Sovaldi. AbbVie will "provide a rebate to states participating in the consortium."

Read more: http://bit.ly/15UL9hm

Source: Fierce Health Payer

Related Videos
Dr Sophia Humphreys
Robert Zimmerman, MD
Video 15 - "Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion"
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Ryan Stice, PharmD
Raajit Rampal, MD, PhD, screenshot
Leslie Fish, PharmD.
Ronesh Sinha, MD
Adam Colborn, JD
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.